Discovery of potent and orally active tricyclic-based FBPase inhibitors

被引：6

作者：

Tsukada, Tomoharu ^{[1
]}

Kanno, Osamu ^{[1
]}

Yamane, Takahiro ^{[1
]}

Tanaka, Jun ^{[2
]}

Yoshida, Taishi ^{[2
]}

Okuno, Akira ^{[2
]}

Shiiki, Takeshi ^{[3
]}

Takahashi, Mizuki ^{[4
]}

Nishi, Takahide ^{[1
]}

机构：

[1] Daiichi Sankyo Co Ltd, Med Chem Res Labs 1, Shinagawa Ku, Tokyo 1408710, Japan

[2] Daiichi Sankyo Co Ltd, Biol Res Labs 2, Shinagawa Ku, Tokyo 1408710, Japan

[3] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan

[4] Daiichi Sankyo Co Ltd, Exploratory Res Labs 1, Edogawa Ku, Tokyo 1348630, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY | 2010年 / 18卷 / 14期

关键词：

Fructose-1,6-bisphosphatase; FBPase inhibitors; Prodrug; MOLECULAR-SURFACE PROPERTIES; FRUCTOSE 1,6-BISPHOSPHATASE; BENZOXAZOLE BENZENESULFONAMIDES; ALLOSTERIC INHIBITORS; GLUCOSE-PRODUCTION; DIABETES-MELLITUS; AMP SITE; FRUCTOSE-1,6-BISPHOSPHATASE; GLUCONEOGENESIS; PERMEABILITY;

D O I：

10.1016/j.bmc.2010.05.041

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

With the aim of exploring the effect of tricyclic-based FBPase inhibitors in cells and in vivo, a series of prodrugs of tricyclic phosphonates was designed and synthesized. Introducing prodrug moieties into tricyclic-based phosphonates led to the discovery of prodrug 15c, which strongly inhibited glucose production in monkey hepatocytes. Furthermore, prodrug 15c lowered blood glucose levels in fasted cynomolgus monkeys. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：5346 / 5351

页数：6

共 50 条

[1] A prodrug approach towards the development of tricyclic-based FBPase inhibitors
Tsukada, Tomoharu
Tamaki, Kazuhiko
Tanaka, Jun
Takagi, Toshiyuki
Yoshida, Taishi
Okuno, Akira
Shiiki, Takeshi
Takahashi, Mizuki
Nishi, Takahide
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2938 - 2941
[2] Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
Velcicky, Juraj
Janser, Philipp
Gommermann, Nina
Brenneisen, Silke
Ilic, Slavica
Vangrevelinghe, Eric
Stiefl, Nikolaus
Boettcher, Andreas
Arnold, Christelle
Malinverni, Claire
Dawson, Janet
Murgasova, Renata
Desrayaud, Sandrine
Beltz, Karen
Hinniger, Alexandra
Dekker, Carien
Farady, Christopher J.
Mackay, Angela
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (02) : 1544 - 1562
[3] Discovery of potent and orally active farnesyltransferase (FT) inhibitors.
Tong, YS
Wang, L
Hasvold, L
Leonard, N
Li, TM
Li, Q
Wang, WB
Cohen, J
Gu, WZ
Zhang, HY
Bauch, J
Marsh, K
Rosenberg, SH
Lin, NH
Sham, HL
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U29 - U29
[4] Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors
Tsukada, Tomoharu
Takahashi, Mizuki
Takemoto, Toshiyasu
Kanno, Osamu
Yamane, Takahiro
Kawamura, Sayako
Nishi, Takahide
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (20) : 5909 - 5912
[5] Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK)
Shakespeare, William
Fantin, Valeria
Wang, Frank
Kohlmann, Anna
Liu, Shuangying
Huang, Wei-Sheng
Wang, Yihan
Zou, Dong
Thomas, Mathew
Li, Feng
Qi, Jiwei
Cai, Lisi
Dwight, Thimothy
Xu, Yongjin
Xu, Rongsong
Dodd, Rory
Xu, Qihong
Anjum, Rana
Zhang, Sen
Keats, Jeffrey
Xue, Ling
Wardwell, Scott
Ning, Yaoyu
Moran, Lauren
Mohemmad, Qurish
Zhu, Xiaotian
Narasimhan, Narayana
Rivera, Victor
Dalgarno, David
Clackson, Tim
CANCER RESEARCH, 2009, 69
[6] Discovery of triazines as potent, selective and orally active PDE4 inhibitors
Gewald, Rainer
Grunwald, Christian
Egerland, Ute
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (15) : 4308 - 4314
[7] Discovery of Highly Potent BET Inhibitors based on a Tractable Tricyclic Scaffold
Zaidi, Jaffer M.
Comeo, Eleonora
Baxter, Andrew
Preston, Alex G. S.
Chan, Weng C.
Stocks, Michael J.
ACS MEDICINAL CHEMISTRY LETTERS, 2025,
[8] Discovery of Potent, Selective, and Orally Active Carboxylic Acid Based Inhibitors of Matrix Metalloproteinase-13
Monovich, Lauren G.
Tommasi, Ruben A.
Fujimoto, Roger A.
Blancuzzi, Vincent
Clark, Kirk
Cornell, Wendy D.
Doti, Robert
Doughty, John
Fang, James
Farley, David
Fitt, John
Ganu, Vishwas
Goldberg, Ronald
Goldstein, Robert
Lavoie, Stacey
Kulathila, Raviraj
Macchia, William
Parker, David T.
Melton, Richard
O'Byrne, Elizabeth
Pastor, Gary
Pellas, Theodore
Quadros, Elizabeth
Reel, Noela
Roland, Dennis M.
Sakane, Yumi
Singh, Hem
Skiles, Jerry
Somers, Joseph
Toscano, Karen
Wigg, Andrew
Zhou, Siyuan
Zhu, Lijuan
Shieh, Wen-Chung
Xue, Song
McQuire, Leslie W.
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (11) : 3523 - 3538
[9] Discovery of Orally Active, Potent, and Selective Benzotriazole-Based PTP1B Inhibitors
Patel, Dipam
Jain, Mukul
Shah, Shailesh R.
Bahekar, Rajesh
Jadav, Pradip
Darji, Brijesh
Siriki, Yernaidu
Bandyopadhyay, Debdutta
Joharapurkar, Amit
Kshirsagar, Samadhan
Patel, Harilal
Shaikh, Mubeen
Sairam, Kalapatapu V. V. M.
Patel, Pankaj
CHEMMEDCHEM, 2011, 6 (06) : 1011 - 1016
[10] Discovery of Orally Active JNK Inhibitors
Satoh, Yoshitaka
INFLAMMATION RESEARCH, 2005, 54 : S134 - S135

← 1 2 3 4 5 →